The NCT 03839771 study is a phase III, randomized, placebo-controlled study on ivosidenib or enasidenib combined with induction and consolidation therapy in newly diagnosed AML or MDS/AREB 2 harboring IDH-mutations. The gene discussed is IDH1; the disease is myelodysplastic syndrome.